SCOTTSDALE, Ariz., Aug. 5, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues for the three months ended June 30, 2008, of approximately $132.5 million, compared to approximately $108.9 million for the three months ended June 30, 2007, representing an increase of approximately 22%. This increase was due primarily to the continued strength of SOLODYN(R). Non-generally accepted accounting principles (non-GAAP) earnings per diluted share for the three months ended June 30, 2008, adjusted only for the $25 million payment to Ipsen for the RELOXIN(R) Biologics License Application (BLA) acceptance by the U.S. Food and Drug Administration (FDA), was approximately $0.40 per diluted share. Comparatively, for the three months ended June 30, 2007, the Company reported non-GAAP earnings per diluted share of $0.28 per diluted share, adjusted only for the write-down of the long-lived asset value associated with OMNICEF(R).
